Intervention not reported
Point‐prevalence abstinence rates at short‐term · adults with cannabis use disorder or frequent cannabis use
The intervention may leads to higher point‐prevalence abstinence rates at short‐term (low certainty).
1 finding from 1 review
Intervention not reported
Cannabis use quantity per day at short‐term · adults with cannabis use disorder or frequent cannabis use
It is very uncertain whether the intervention changes cannabis use quantity per day at short‐term (very low certainty).
1 finding from 1 review
Intervention not reported
Symptoms of dependence at short‐term · adults with cannabis use disorder or frequent cannabis use
The intervention may leads to higher symptoms of dependence at short‐term (low certainty).
1 finding from 1 review
Intervention not reported
Cannabis‐related problems at short‐term · adults with cannabis use disorder or frequent cannabis use
The intervention may leads to higher cannabis‐related problems at short‐term (low certainty).
1 finding from 1 review
Intervention not reported
Retention in treatment · adults with cannabis use disorder or frequent cannabis use
1 finding from 1 review
Intervention not reported
Retention at treatment completion (CM vs. control)
The intervention showed no clear difference in retention at treatment completion (CM vs. control) (low certainty).
1 finding from 1 review
Successful discontinuation of BZDs‐ post treatment Objective and subjective · patients with BZD harmful use, abuse or dependence
CBT (plus taper) probably leads to higher successful discontinuation of BZDs‐ post treatment Objective and… compared with taper (moderate certainty).
1 finding from 1 review
Successful discontinuation of BZDs‐ 12 month · patients with BZD harmful use, abuse or dependence
CBT (plus taper) showed no clear difference in successful discontinuation of BZDs‐ 12 month compared with taper (moderate certainty).
1 finding from 1 review
Reduce BZDs> 50% ‐ post treatment Objective · patients with BZD harmful use, abuse or dependence
CBT (plus taper) showed no clear difference in reduce BZDs> 50% ‐ post treatment Objective compared with taper (low certainty).
1 finding from 1 review
Reduce BZDs> 50% ‐ 12 month · patients with BZD harmful use, abuse or dependence
CBT (plus taper) showed no clear difference in reduce BZDs> 50% ‐ 12 month compared with taper (low certainty).
1 finding from 1 review
Successful discontinuation of BZDs‐ post treatment Objective and subjective · patients with BZD harmful use, abuse or dependence
It is very uncertain whether MI changes successful discontinuation of BZDs‐ post treatment Objective and… compared with TAU (very low certainty).
2 findings from 1 review
Criminal activity dichotomous ‐ Reincarceration official records · patients with drug‐using offenders
Summary of findings for the main comparisons: Antagonost (Naltrexone) probably leads to lower criminal activity dichotomous ‐ Reincarceration official records compared with no pharmacological (moderate certainty).
1 finding from 1 review
Drug use · patients with drug‐using offenders
Summary of findings for the main comparisons: Antagonost (Naltrexone) showed no clear difference in drug use (objective) urine screen compared with no pharmacological (low certainty).
1 finding from 1 review